Twist Bioscience (TWST) grants director Katryn Blake 5,095-share award

Rhea-AI Filing Summary

Twist Bioscience director Katryn Blake reported a new stock grant. On February 5, 2026, she acquired 5,095 shares of common stock at $0 per share as an annual equity award. Following this grant, she beneficially owns 19,448 common shares, held directly.

The award vests 100% on the earlier of the one-year anniversary of the grant date or the first annual stockholder meeting after the grant, as long as she continues serving as a non-employee director on the applicable vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BLAKE KATRYN

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2026		A		5,095(1)	A	$0	19,448	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Katryn Blake	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Twist Bioscience (TWST) disclose in this Form 4 filing?

Twist Bioscience disclosed that director Katryn Blake received an annual equity award of 5,095 common shares on February 5, 2026. The shares were granted at $0 per share and increase her directly held beneficial ownership.

How many Twist Bioscience (TWST) shares does Katryn Blake now beneficially own?

After the reported equity award, director Katryn Blake beneficially owns 19,448 shares of Twist Bioscience common stock. This total reflects the newly granted 5,095 shares added to her prior holdings, all reported as directly owned in the Form 4.

What are the vesting terms of Katryn Blake’s 5,095-share award at Twist Bioscience?

The 5,095-share annual equity award will vest 100% on the earlier of the one-year anniversary of the February 5, 2026 grant date or the first annual stockholder meeting afterward, provided she remains a non-employee director on the vesting date.

Was Katryn Blake’s Twist Bioscience stock award a market purchase?

No. The Form 4 shows transaction code "A" with a price of $0 per share, indicating an equity grant rather than an open-market purchase. It represents compensation in stock, not a cash-funded acquisition.

Is Katryn Blake a 10% owner of Twist Bioscience (TWST) based on this filing?

No. The reporting information identifies Katryn Blake as a director of Twist Bioscience and does not classify her as a 10% owner. The filing focuses on her role as a non-employee director receiving an annual equity award.